TY  - JOUR
AU  - Lodde, Georg Christian
AU  - Krefting, Frederik
AU  - Placke, Jan-Malte
AU  - Schneider, Lea
AU  - Fiedler, Melanie
AU  - Dittmer, Ulf
AU  - Becker, Jürgen
AU  - Hölsken, Stefanie
AU  - Schadendorf, Dirk
AU  - Ugurel, Selma
AU  - Sondermann, Wiebke
TI  - COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.
JO  - Frontiers in immunology
VL  - 14
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2023-00679
SP  - 1107438
PY  - 2023
AB  - The rate of seroconversion after COVID-19 vaccination in patients with moderate to severe psoriasis requiring systemic treatment is poorly understood.The aim of this prospective single-center cohort study performed between May 2020 and October 2021 was to determine the rate of seroconversion after COVID-19 vaccination in patients under active systemic treatment for moderate to severe psoriasis.Inclusion criteria were systemic treatment for moderate to severe psoriasis, known COVID-19 vaccination status, and repetitive anti-SARS-CoV-2-S IgG serum quantification. The primary outcome was the rate of anti-SARS-CoV-2-S IgG seroconversion after complete COVID-19 vaccination.77 patients with a median age of 55.9 years undergoing systemic treatment for moderate to severe psoriasis were included. The majority of patients received interleukin- (n=50, 64.9
KW  - COVID-19 vaccines (Other)
KW  - biologics (Other)
KW  - psoriasis (Other)
KW  - psoriasis treatment (Other)
KW  - seroconversion (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37006279
C2  - pmc:PMC10061348
DO  - DOI:10.3389/fimmu.2023.1107438
UR  - https://inrepo02.dkfz.de/record/275221
ER  -